The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections - As weight-loss injections emerge as key players in ...
Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...
There were no discontinuations of the drug at the highest dose ... looking to maintain their weight loss, or ...
Lilly last week reported a rare $1.5 billion sales miss for its injectable obesity drug Zepbound and ... again be in focus when Novo reports results for its diabetes drug Ozempic and ...
The FDA urges healthcare professionals to stop administering the products, and patients should stop using them.
Data reported earlier Monday from Viking Therapeutics (NASDAQ:VKTX) on its weight loss medicine VK2735 indicates that Novo ...